NCT05695573View on ClinicalTrials.gov

Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

April 28, 2022

Study Completion Date

June 1, 2022

Conditions
Diabetic Nephropathy
Interventions
DIAGNOSTIC_TEST

ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile

Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis

Trial Locations (1)

31515

Tanta university hospital, faculty of science, tanta university, Tanta

All Listed Sponsors
collaborator

Ain Shams University

OTHER

lead

Tanta University

OTHER

NCT05695573 - Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy | Biotech Hunter | Biotech Hunter